Articles tagged with Tumor Growth
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A study by Tulane University researchers found that tumors in female fruit flies grew 2.5 times larger than those in male fruit flies due to sex-based differences in immune response. The stronger innate immune response in females accelerated tumor growth.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
Researchers at Sanford Burnham Prebys found that pancreatic cancer cells rely on a specific nutrient, glutamine, to fuel their unchecked growth. The study identified two enzymes, aPKC zeta and iota, that play a regulatory role in the process of macropinocytosis, allowing cancer cells to scavenge alternative resources.
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
A study published in Nature reveals that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer. The liver converts fructose into usable nutrients for cancer cells, a finding that could lead to new treatment avenues.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
Researchers activate glycoprotein 130 and its associated signaling pathway to slow down tumor growth in prostate cancer, stimulating immune system to fight tumour cells. Studies of tissue samples from prostate cancer patients show positive correlation with better survival rates.
Mesenchymal stem cells (MSCs) show promise in delivering treatments directly to cancer cells and boosting the immune system's fight against cancer. However, ongoing research highlights challenges related to MSC behavior, including variability in their effects and potential to create conditions that support tumor growth.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
Researchers discovered that cancer grows uniformly throughout its mass, with every region equally active and potentially harboring aggressive mutations. This finding challenges the traditional 'two-speed' entity model of tumors, where rapidly dividing cells on the surface and slower activity in the core were thought to exist.
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers found that non-invasive stereotactic radiosurgery significantly improves tumor control and reduces symptoms such as tinnitus, cranial nerve deterioration, and vestibular dysfunction. Early treatment can prevent tumors from growing over time and spare patients from irreversible problems.
A study by Texas A&M University has revealed high levels of lead, barium, and chromium in soil samples from the Greater Fifth Ward neighborhood. The findings highlight the need for environmental protection programs to address health risks associated with heavy metal exposure.
A new University of Cincinnati Cancer Center study reveals how copper helps clear cell renal cell carcinoma cells grow and advance. Copper accumulation is associated with worse outcomes for patients with ccRCC, and it boosts energy and growth in cancer cells.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
The TTUHSC team will conduct a needs assessment and create an action plan to strengthen clinical and community-based research, guided by strategic translational research themes. The goal is to address health disparities in the region through community-based participatory research.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
A study published in the Chinese Medical Journal projects a significant rise in global thyroid cancer burden, with 821,214 new cases and 47,507 related deaths reported worldwide in 2022. The incidence is expected to increase by 44.1% from 2019 to 2030, with women experiencing higher rates than men.
Researchers at Umea University have discovered how embryonic stem cells transition into specialized cells, highlighting the importance of LSD1 protein in cancer development. The study suggests that targeting only LSD1's enzymatic activity may not be enough for cancer treatments to be effective.
Researchers have identified a critical genetic group that is near incurable using current therapies, leading to improved survival and quality of life for children with Group 3 medulloblastoma. The study also uncovered a potential targetable mechanism for new therapies aimed at improving outcomes.
A study by Ohio State University researchers found that combining pimozide with CB-839 can effectively suppress glioblastoma growth by blocking lipid production and starvation of tumor cells. This innovative combination may also hold promise for treating other cancers relying on glutamine and lipids.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
Researchers discovered TERT gene activation as a key factor in determining the clinical course of pulmonary carcinoid tumours, with aggressive growth linked to telomerase activation. The study aims to improve treatment planning and targeted therapeutic strategies for cancer types.
Researchers at MUSC Hollings Cancer Center have developed a new model for ovarian cancer that suggests serous uterine cancer may originate in the fallopian tubes, rather than the uterus. The model has already shown promising results in replicating high-grade serous ovarian and uterine cancers.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
A new study published in Frontiers in Immunology reveals that certain food proteins like milk and meat can help keep gut tumors from growing by triggering the intestinal immune system. This discovery has potential clinical implications for patients with gastrointestinal conditions.
The University of Oklahoma Health Sciences has received a $5.3 million National Institutes of Health grant to support advanced cancer research in Oklahoma. The grant will help early-career researchers establish independently funded laboratories and build technology infrastructure specific to cancer investigations.
Researchers at UCSF used cryogenic electron microscopy to study the protein TGF-Beta, which plays a crucial role in development and cancer. They found that TGF-Beta can signal even when bound to a 'straitjacket' within the cell membrane, challenging decades-old dogma on its function.
Researchers discovered a key molecule, PAF, that controls the destiny of immune cells and turns them against cancer. The study highlights the importance of targeting PAF to develop new therapies for various types of cancer.
Researchers highlight key phagocytosis checkpoints and 'do not eat me' signals as potential therapeutic targets for novel immunotherapies. The editorial summarizes challenges in targeting CD47 and potential solutions to overcome these obstacles.
A new study found that cystic fibrosis patients with more severe disease characteristics exhibit shorter leukocyte telomere length and greater LTL attrition. This association may accelerate aging and increase susceptibility to age-related diseases, emphasizing the importance of early CF diagnosis and timely therapeutic intervention.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
Researchers propose a new approach to understanding cancer evolution, acknowledging the importance of environmental influences and epigenetic changes. By refining the clonal evolution model, they aim to develop more effective cancer therapies that consider the full complexity of cancer cell evolution.
A glitch in protein synthesis, known as stop codon readthrough, may affect tumour growth and cancer cell proliferation. The study found that preventing this process can lead to increased degradation of target proteins and a delayed cell cycle, resulting in slower tumour growth.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
A common skin fungus, Malassezia globosa, may invade deep tissues and cause tumor growth in breast cancer, according to a new study published in mBio. The researchers found that M. globosa colonizes in breast fat pads leading to tumor growth, suggesting a potential link between fungal colonization and cancer progression.
A new study reveals that the menstrual cycle plays a role in spreading mutant cells within mammary tissue, leading to large fields prone to tumor formation. Researchers observed that the growth and removal of extra milk ducts during the menstrual cycle can contribute to this process.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
Researchers create superhydrophobic array device (SHArD) mimicking the lotus leaf surface structure, enabling high-throughput generation of three-dimensional nanoscale tumor models. This platform helps study metastasis and primary tumors, shedding light on cancer progression.
Researchers found that targeting and silencing ERBB2 gene expression significantly increases chances of stopping tumor growth in mice with a PTEN mutation. This breakthrough may lead to alternative treatment options for endometrial cancer patients, reducing the risk of fertility issues associated with standard treatments.
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
Researchers discuss diverse BRAF alterations found in human cancers and strategies to inhibit them. Class I BRAF inhibitors represent a landmark achievement in precision oncology, with FDA-approved dabrafenib/trametinib for metastatic BRAF p.V600E-mutant solid tumors.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
Researchers discuss how PROM2 is a predictive biomarker of distant metastases and shorter survival among patients with stage III melanomas. They also demonstrate that runaway metastasis is closely linked to PROM2 overexpression, through increased epithelial-to-mesenchymal transition marker expression and ferroptosis resistance.
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
A new clinical algorithm developed at the University of Gothenburg can accurately identify highly aggressive forms of basal cell carcinoma. The algorithm uses a combination of clinical and dermoscopic images to distinguish between low-risk and high-risk tumors, allowing for more effective treatment and better patient outcomes.
Researchers analyzed collision-type mixed ductal-lobular breast cancers and found that IDC and ILC regions had distinct gene expression profiles. The study reveals tremendous variation within this already highly variable disease, highlighting the need for personalized treatments.
Researchers discovered that OTX2 interacts with splicing factors to control alternative splicing in genes fueling medulloblastoma development. Disturbing the PPHLN1 gene splicing with an anti-PPHLN1 drug reduces tumor growth, opening possibilities for improved treatments.
Researchers at Tufts University have identified the immune cells driving cardiac inflammation in cancer patients taking doxorubicin, a commonly used chemotherapy drug. Blocking these cells could potentially prevent cardiac damage and make treatment safer for patients.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
Patients with mantle cell lymphoma are more vulnerable to other diseases and infections due to intensive chemotherapy and a weakened immune system. A large-scale national study found that MCL patients had twice as many infections as reference subjects, with common causes including influenza and urinary tract infections.